NeuAura Medical offers the EuphAura system, a non‑invasive oxytocin neuromodulation solution that combines an adhesive transdermal gel patch with a small wireless skin‑stimulating device to trigger the body’s own oxytocin production.
Funding
Funding not disclosed
Founders
Product
Problem
Many women experiencing stress, anxiety disorders, and depression have limited access to treatments that are both non‑pharmacological and capable of directly influencing hormonal pathways linked to mood regulation.
Solution
NeuAura Medical’s EuphAura system delivers non‑invasive oxytocin neuromodulation by combining an adhesive transdermal gel patch with a small wireless skin‑stimulating device. The device activates mechanoreceptors in the skin, prompting the body to produce and release oxytocin into the bloodstream and brain, leveraging the hormone’s natural role in mood regulation and social bonding. Dosing and session monitoring are managed through a companion mobile app, allowing users to self‑administer therapy at home with precise control. This approach provides a drug‑free method to boost endogenous oxytocin levels, aiming to alleviate symptoms of stress, anxiety, and depression.
Target Audience
Primary users are women seeking non‑pharmacological mental‑health solutions for stress, anxiety, and depression, including individuals preferring self‑managed, hormone‑based wellness approaches.
Features
- Adhesive transdermal gel patch that facilitates continuous skin contact for consistent stimulation
- Wireless neuromodulation device that emits targeted mechanical pulses to activate cutaneous mechanoreceptors
- Mobile EuphAura app for personalized dosing schedules, session tracking, and real‑time feedback
- Closed‑loop design that relies on the body’s own oxytocin production rather than external hormone administration
- Portable, battery‑operated hardware enabling discreet, at‑home use without clinical supervision